Arrhythmias and Conduction DisturbancesImpact of Gender on the Prognosis of Patients With Nonvalvular Atrial Fibrillation
Section snippets
Methods
The details of the study design,14 the subjects' characteristics,15 and the main analyses16 have been reported elsewhere. Briefly, the study protocol conformed to the Declaration of Helsinki and was approved by each of the participating institutions. Consecutive patients with AF were recruited at the outpatient clinic of each participating institution from January 2009 to July 2009. All the patients gave their written informed consent. Patients who had maintained sinus rhythm for >1 year with
Results
Of the 7,516 patients with NVAF enrolled in the J-RHYTHM registry, 110 (2%) were lost to follow-up. Therefore, the remaining 7,406 patients constituted the study group for this subanalysis (Table 1). There were 5,241 men and 2,165 women in the study population. Compared with male patients with AF, female patients were older and displayed greater prevalences of paroxysmal AF, heart failure and hypertension but less prevalences of diabetes, previous CI or TIA, cardiomyopathy, and coronary artery
Discussion
The present subanalysis of the J-RHYTHM registry,14, 15, 16 in which approximately 86% of the participants received warfarin, revealed the following major findings regarding sex-related differences in the prognosis of Japanese patients with NVAF. Female gender did not emerge as an independent risk factor for thromboembolism. In addition, being an elderly woman of ≥75 years of age was not found to be a risk factor for thromboembolism compared with being an elderly man of the same age. In
Disclosures
Dr. Inoue reports receiving research fund from Boehringer Ingelheim and Daiichi-Sankyo, and remuneration from Daiichi-Sankyo, Bayer Healthcare, and Boehringer Ingelheim; Dr. Atarashi receiving research fund from Daiichi-Sankyo and Boehringer Ingelheim, and lecture fees from Bayer Healthcare and Boehringer Ingelheim; Dr. Okumura receiving research fund from Boehringer Ingelheim and Daiichi-Sankyo, and remuneration from Boehringer Ingelheim, Bayer Healthcare, Daiichi-Sankyo, and Pfizer; Dr.
References (30)
- et al.
Prevalence of atrial fibrillation in the general population of Japan; an analysis based on periodic health examination
Int J Cardiol
(2009) - et al.
Adequacy of antithrombotic therapy and gender differences in hypertensive patients with atrial fibrillation
Int J Cardiol
(2012) - et al.
Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on atrial fibrillation
J Am Coll Cardiol
(2007) - et al.
Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation
Chest
(2010) - et al.
Mortality trends in patients diagnosed with first atrial fibrillation. A 21-year community-base study
J Am Coll Cardiol
(2007) - et al.
Risk factors for thromboembolism in patients with paroxysmal atrial fibrillation
Am J Cardiol
(2000) - et al.
Chronic kidney disease and CHADS2 score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation
Am J Cardiol
(2011) - et al.
Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation: the J-RHYTHM Registry study design
J Cardiol
(2011) - et al.
Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)
Am Heart J
(2006) - et al.
A new use-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey
Chest
(2010)
Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy; an ACTIVE W substudy
J Am Coll Cardiol
Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score
Heart Rhythm
Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention. The AnTicoagulation and Risk factors in Atrial fibrillation (ATRIA) study
JAMA
Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors in Atrial fibrillation (ATRIA) study
Circulation
Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials
Eur Heart J
Cited by (0)
This study was planned by the Japanese Society of Electrocardiology and supported by a grant from the Japan Heart Foundation, Tokyo, Japan.
This study is registered at UMIN Clinical Trials Registry (UMIN000001569).
See page 961 for disclosure information.